247 related articles for article (PubMed ID: 19942480)
1. Improved first-line chemotherapy: a better chance for surgery?
Tejpar S; Van Cutsem E; Adam R
Lancet Oncol; 2010 Jan; 11(1):4-5. PubMed ID: 19942480
[No Abstract] [Full Text] [Related]
2. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
[TBL] [Abstract][Full Text] [Related]
3. [Results of neo-adjuvant chemotherapy by FOLFOX and FOLFIRI for colorectal liver metastasis].
Amano R; Yamada N; Noda E; Kubo N; Tanaka H; Muguruma K; Inoue T; Yashiro M; Maeda K; Onoda N; Sawada T; Nakata B; Ohira M; Ishikawa T; Hirakawa K
Gan To Kagaku Ryoho; 2009 Nov; 36(12):2003-5. PubMed ID: 20037305
[TBL] [Abstract][Full Text] [Related]
4. Should FOLFOXIRI plus bevacizumab Be the standard first-line therapy in metastatic colorectal cancer?
Nipp RD; Ryan DP
Oncologist; 2015 Mar; 20(3):236-8. PubMed ID: 25660156
[TBL] [Abstract][Full Text] [Related]
5. Recurrent disease four years after surgery and adjuvant chemotherapy.
Pozzo C; Barone C
Cancer Treat Rev; 2008; 34 Suppl 2():S8-11. PubMed ID: 19101406
[TBL] [Abstract][Full Text] [Related]
6. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP
Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168
[TBL] [Abstract][Full Text] [Related]
7. [Choice of surgical strategy for colorectal liver metastases depending on clinical and pathological response to neoadjuvant chemo- and targeted therapy].
Jakab F
Orv Hetil; 2010 Nov; 151(47):1956-60. PubMed ID: 21071308
[TBL] [Abstract][Full Text] [Related]
8. Perforating dermatosis in a patient receiving bevacizumab.
Vano-Galvan S; Moreno C; Medina J; Pérez-García B; García-López JL; Jaén P
J Eur Acad Dermatol Venereol; 2009 Aug; 23(8):972-4. PubMed ID: 19470057
[No Abstract] [Full Text] [Related]
9. Management of patients with synchronous liver metastases of colorectal cancer. Clinical practice guidelines. Guidelines of the French society of gastrointestinal surgery (SFCD) and of the association of hepatobiliary surgery and liver transplantation (ACHBT). Short version.
Zalinski S; Mariette C; Farges O; ; ;
J Visc Surg; 2011 Jun; 148(3):e171-82. PubMed ID: 21703959
[No Abstract] [Full Text] [Related]
10. Surgical removal of metastases after successful treatment containing bevacizumab in metastatic colorectal cancer.
Afonso S; Viani G; Afonso V; Stefano E; Afonso S
Anticancer Drugs; 2011 Jun; 22 Suppl 2():S21-3. PubMed ID: 21768794
[TBL] [Abstract][Full Text] [Related]
11. Conversion chemotherapy using cetuximab plus FOLFIRI followed by bevacizumab plus mFOLFOX6 in patients with unresectable liver metastases from colorectal cancer.
Uehara K; Ishiguro S; Hiramatsu K; Nishio H; Takeuchi E; Takahari D; Yoshioka Y; Takahashi Y; Ebata T; Yoshimura K; Muro K; Nagino M
Jpn J Clin Oncol; 2011 Oct; 41(10):1229-32. PubMed ID: 21840871
[TBL] [Abstract][Full Text] [Related]
12. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
[TBL] [Abstract][Full Text] [Related]
13. The use cetuximab after oxaliplatin-based chemotherapy in a patient with metastatic colorectal cancer.
Malik Z; Eng C
Clin Adv Hematol Oncol; 2007 Jan; 5(1 Suppl 1):4-7. PubMed ID: 17491584
[No Abstract] [Full Text] [Related]
14. NCCN guideline updates: colon and rectal cancers, version 1.2004.
National Comprehensive Cancer Network
J Natl Compr Canc Netw; 2004 Jul; 2(4):284-5. PubMed ID: 19795595
[No Abstract] [Full Text] [Related]
15. Optimizing oxaliplatin-based therapy in metastatic colorectal cancer.
Cassidy J
Clin Adv Hematol Oncol; 2008 May; 6(5):360-1. PubMed ID: 18516025
[No Abstract] [Full Text] [Related]
16. Chemotherapy for the conversion of unresectable colorectal cancer liver metastases to resection.
Power DG; Kemeny NE
Crit Rev Oncol Hematol; 2011 Sep; 79(3):251-64. PubMed ID: 20970353
[TBL] [Abstract][Full Text] [Related]
17. Pathologic complete response to neoadjuvant FOLFOX in combination with bevacizumab in unresectable metastatic colorectal carcinoma.
Duffy A; Shia J; Huitzil-Melendez FD; Fong Y; O'Reilly EM
Clin Colorectal Cancer; 2008 Mar; 7(2):140-3. PubMed ID: 18501074
[TBL] [Abstract][Full Text] [Related]
18. The timing of surgery for resectable metachronous liver metastases from colorectal cancer: Better sooner than later? A retrospective analysis.
Scartozzi M; Siquini W; Galizia E; Stortoni P; Marmorale C; Berardi R; Fianchini A; Cascinu S
Dig Liver Dis; 2011 Mar; 43(3):194-8. PubMed ID: 20728416
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy and regional therapy of hepatic colorectal metastases: expert consensus statement.
Bartlett DL; Berlin J; Lauwers GY; Messersmith WA; Petrelli NJ; Venook AP
Ann Surg Oncol; 2006 Oct; 13(10):1284-92. PubMed ID: 16955384
[No Abstract] [Full Text] [Related]
20. Second line therapies move to the forefront in colorectal cancer.
Miller M
J Natl Cancer Inst; 1999 Jun; 91(12):998-1000. PubMed ID: 10379961
[No Abstract] [Full Text] [Related]
[Next] [New Search]
